Steimer Desiree A, Hernandez Omar, Ogola Gerald, Mason David P, Schwartz Gary S
Department of Thoracic Surgery, Brigham and Women's HospitalBostonMassachusetts.
Department of Perfusion Services, Baylor University Medical CenterDallasTexas.
Proc (Bayl Univ Med Cent). 2019 Oct 25;33(1):5-9. doi: 10.1080/08998280.2019.1669120. eCollection 2020 Jan.
Venovenous extracorporeal membrane oxygenation (ECMO) has emerged as an important tool in the treatment of acute respiratory distress syndrome (ARDS). The creation of portable ECMO circuits and pumps has supported the development of interfacility ECMO programs. Prior studies have demonstrated that ECMO transport is safe; however, long-term outcomes for these patients remain unknown. Retrospective analysis of our 5-year experience identified 58 patients transported on ECMO and 82 patients cannulated at our institution. When short-term (30 days) and long-term (1 year) outcomes were compared between these cohorts, there was no statistically significant difference in survival ( = 0.44 and 0.49). There were no deaths related to transport, and the rate of ECMO-related complications was similar between the groups. With established patient safety and similar long-term survival, ECMO transport is a feasible solution to provide access to ECMO for all communities.
静脉-静脉体外膜肺氧合（ECMO）已成为治疗急性呼吸窘迫综合征（ARDS）的一项重要工具。便携式ECMO回路和泵的出现推动了院际ECMO项目的发展。既往研究表明，ECMO转运是安全的；然而，这些患者的长期预后仍不明确。对我们5年经验的回顾性分析确定了58例接受ECMO转运的患者以及82例在我们机构进行插管的患者。当比较这些队列的短期（30天）和长期（1年）预后时，生存率无统计学显著差异（P = 0.44和0.49）。没有与转运相关的死亡，两组之间ECMO相关并发症的发生率相似。鉴于已确立的患者安全性和相似的长期生存率，ECMO转运是为所有社区提供ECMO治疗机会的可行解决方案。
